Compare · HYPR vs TMDX
HYPR vs TMDX
Side-by-side comparison of Hyperfine Inc. (HYPR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.46B, about 17.6x HYPR ($140.0M).
- Over the past year, HYPR is up 79.9% and TMDX is down 49.0% - HYPR leads by 128.9 points.
- TMDX has been more active in the news (12 items in the past 4 weeks vs 11 for HYPR).
- TMDX has more recent analyst coverage (18 ratings vs 4 for HYPR).
- Company
- Hyperfine Inc.
- TransMedics Group Inc.
- Price
- $1.41+0.36%
- $71.18+2.61%
- Market cap
- $140.0M
- $2.46B
- 1M return
- -16.86%
- -2.27%
- 1Y return
- +79.90%
- -48.97%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 11
- 12
- Recent ratings
- 4
- 18
Hyperfine Inc.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest HYPR
- SEC Form 4 filed by Director Wolterman Dan
- CFO and CAO Hale Brett sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 1.00% to 599,765 units (SEC Form 4)
- Chief Operating Officer Teisseyre Thomas sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 0.88% to 678,601 units (SEC Form 4) (withholding obligation)
- Hyperfine to Join Russell 2000® and Russell 3000® Indexes
- SEC Form 4 filed by Director Fattori Ruth A
- SEC Form 4 filed by Director Wolterman Dan
- SEC Form 4 filed by Director Dahldorf John T
- SEC Form 4 filed by Director Rothberg Jonathan M
- Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
- SEC Form EFFECT filed by Hyperfine Inc.
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.